Gapping up
In reaction to earnings/guidance:
- BBBY +16.8%, STM +6.5% (sees Q3 and FY20 revs above consensus) SNN +3.9% (Q3 guidance) CAG +2.5%, PEP +1.5%
Select airline stocks trading higher:
- JBLU +2.4%, JETS +2.2%, UAL +1.9%, AAL +1.9%, DAL +1.6%, LUV +1.5%, ALK +1.4%, .
Other news:
- SLDB +70.9% (FDA has lifted the clinical hold placed on the Company's IGNITE DMD Phase I/II clinical trial)
- ADES +66.3% (Cabot [CBT] announced long-term supply agreement with co)
- AMAG +42% (in talks to be acquired by Covis Pharma, per Bloomberg)
- SBH +7% (to join the S&P SmallCap 600)
- SAIL +6.6% (to join the S&P MidCap 400)
- PRVB +5.9% (announced submission of clinical module for teplizumab BLA)
- FLR +4.4% (awarded $1.1 bln Navy contract)
- KLDO +3.9% (announced that Daniel Menichella has been appointed President and CEO)
- PLTR +3.5% (continued volatility following public debut)
- AMC +3% (to reopen additional theaters in California and Michigan)
- RGEN +2.9% (announced their successful development of an affinity ligand targeting the spike protein, to be utilized in the purification of COVID-19 vaccines)
- KDMN +2.8% (submitted NDA for belumosudil for the treatment of patients with cGVHD)
- GTHX +2.5% (announced CEO succession plan; lightly traded)
- VYNE +2.4% (announces its novel ZILXI topical foam, 1.5% is available as of today by prescription for the treatment of inflammatory lesions of rosacea in adults)
- FMCI +1.9% (stockholders approve extending date to complete business combination to October 30)
- NVS +1.7% (presents new interim Phase 3 STR1VE-EU data demonstrating therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement)
- IONS +1.2% (ION373 received orphan drug designation for the treatment of Alexander disease)
Analyst comments:
- AZUL +7.4% (upgraded to Buy from Neutral at Goldman)
- AEG +7% (upgraded to Overweight from Neutral at JP Morgan)
- CATB +6.6% (initiated with Buy at HC Wainwright)
- DKNG +5% (initiated with a Buy at Needham)
- GT +4.7% (upgraded to Buy from Neutral at Northcoast)
- KAR +4.2% (upgraded to Overweight rom Equal-Weight at Stephens)
- MT +3.9% (upgraded to Buy from Hold at Kepler)
- GOL +3.6% (upgraded to Buy from Neutral at Goldman)
- SYNH +3.1% (upgraded to Buy from Neutral at Goldman)
- WDAY +2.3% (resumed with a Buy from Neutral at Citigroup)
- LHX +2% (upgraded to Buy from Neutral at UBS)
- AMZN +1.7% (target raised to $4500 from $3925 at Pivotal Research Group)
- DVN +1.2% (upgraded to Buy from Hold at Truist)
- CAE +1% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- VLRS +1% (upgraded to Buy from Neutral at Goldman)